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consistently assist clinicians in their
understanding of CIU’s pathogenesis.
What is truly needed is a reproducible
assay to advance the specific definition
of autoimmune urticaria.
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TO THE EDITOR
The goal of this study is to gain insight
into putative pathways by which 13-cis
retinoic acid (13-cisRA) improves
acne by comparing the temporal
changes in gene expression in the skin
of acne patients. Gene array analysis
and immunohistochemistry were
performed on skin biopsies from
patients at baseline and after 8 weeks
of isotretinoin therapy and compared to
data obtained at 1 week (Nelson et al.,
2008).
As 13-cisRA drastically decreases
sebaceous gland size after 16 weeks
(Goldstein et al., 1982); we chose an 8-
week time point to examine changes in
skin histology and gene expression. All
protocols were approved by the Institu-
tional Review Board of The Pennsylva-
nia State University College of
Medicine and were conducted accord-
ing to the principles outlined in the
Declaration of Helsinki. Eight patients
who were prescribed isotretinoin for
their severe acne enrolled in the study
after giving informed consent and
5-mm punch biopsies of uninvolved
skin were taken from their upper backs
at baseline and 8 weeks of treatment.
Demographic data are presented in
Figure 1a. After 8 weeks, sebaceous
gland size was reduced by 76% (4.17-
fold) compared to baseline (P¼0.009)
(Figure 1b and d). At 1 week, glands
were decreased by approximately 49%
(not significant; Figure 1c and d).
Gene array expression analysis was
performed on biopsies at baseline and
after 8 weeks of therapy. Using a false
discovery rate of 0.05 corresponding toAbbreviation: 13-cisRA, 13-cis retinoic acid
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a 5% chance of false positives, 197
genes were significantly upregulated
and 587 genes were significantly
downregulated. Select genes are listed
in Table 1 (complete list, S1). The
preponderance of genes that were
downregulated at 8 weeks involve the
metabolism of steroids, cholesterol, and
fatty acids, consistent with the known
decreases in sebum production induced
by 13-cisRA. Upregulated genes at 8
weeks encode structural proteins such
as collagens and fibronectin, consistent
with the known effects of retinoids in
rebuilding extracellular matrix (Weiss
et al., 1988; Griffiths et al., 1993; Kafi
et al., 2007). In comparison, at 1 week,
significant increases in expression were
noted in genes broadly categorized as
tumor suppressors, protein processors,
and genes involved in transfer or bind-
ing of ions and small molecules (Nelson
et al., 2008).
Only three genes were found in
common between the 1-week and 8-
week gene arrays illustrating that iso-
tretinoin regulates the temporal expres-
sion of separate and distinct groups of
genes. These three genes were down-
regulated 2- to 5-fold and include
solute carrier family 26, member 3
(SLC26A3); phospholipase A2, group
VII (PLA2G7); and phosphodiesterase
6A (PDE6A). PLA2 family members
hydrolyze membrane phospholipids to
generate arachidonic acid, a known
inflammatory mediator (Yedgar et al.,
2006). Retinoids, including 13-cisRA,
inhibit PLA2 activity and prevent
8-Week patient demographics
Subject no. Age Sex
F
M
Dose
mg kg–1 day
1
1
1
1
0.5
0.67
0.5
0.83 ± 0.23 9.12 ± 1.1
1 9
8
11
9
10
10
8
8
Biopsy
(weeks)
F
M
M
F
M
M
22
17
32
15
18
24
14
15
19.6 ± 6
1
2
3
4
5
6
7
8
Mean ± SD
8 week
1 week
Baseline
Pt 2
Pt 6
Pt 8
M
ea
n 
se
ba
ce
ou
s 
gl
an
d 
siz
e
(m
m2
) ±
 
SE
M
8 week 1 week
P = 0.11
Before
During
*
0.35
0.3
0.25
0.2
0.15
0.1
0.05
–0.05
–0.1
0
Baseline
During
During
Pt 1
Pt 2
Pt 3
Figure 1. Sebaceous gland size is significantly reduced by isotretinoin at 8 weeks of treatment compared to 1 week. (a) Patient demographics. (b–d)
Hematoxylin and eosin sections of skin biopsies were taken from patients before and at approximately 8 weeks or 1 week of isotretinoin treatment. A total of 16
sections at baseline and 12 sections at 8 weeks of treatment were taken from 8 patients and analyzed using Image Pro Plus computer software. The mean area
(±SEM) of sebaceous glands in the baseline samples was 0.17±0.04mm2 compared to 0.04±0.07mm2 in the 8-week samples; a 4.17-fold reduction in size
(P¼0.009). A total of 17 sections at baseline and 19 sections at 1 week of treatment were taken from six patients and analyzed using image analysis software. In
contrast to 8 weeks of isotretinoin treatment, the mean area (±SEM) of sebaceous glands in the 1-week baseline samples was 0.23±0.09mm2 compared to
0.12±0.02mm2 after 1 week of treatment, which was not significant using a paired t-test (P¼0.16). Representative images from three patients at each time
point are shown at original magnification of  100. Scale bars¼250 mm.
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arachidonic acid release in human
synovial fluid which may explain its
anti-inflammatory properties (Hope
et al., 1990). PDEA6 encodes the
cyclic-GMP-specific PDE6A a-subunit
expressed in cells of the retinal rod
outer segment. Mutations in PDE6A
occur in autosomal recessive retinitis
pigmentosa, which is associated with
night blindness (Wang et al., 2001).
Although night blindness is a known
potential side effect of isotretinoin
treatment, it has not been linked
with changes in retinal expression of
PDE6A.
To determine if 13-cisRA preferen-
tially influences a particular subset of
genes, genes were categorized accord-
ing to their ‘‘gene ontology’’, ‘‘protein
domains’’, ‘‘chromosomal location’’,
and ‘‘pathway’’ annotations using
dChip software. For the 8-week data,
21 protein domains and 10 pathways
were significantly enriched (Po0.001).
Protein domains for collagen and fibro-
nection were significantly increased.
Domains for steroid metabolizing
enzymes were decreased. Ten path-
ways were downregulated; each is
linked to lipid metabolism, further
Table 1. Select genes significantly changed by 8 weeks of 13-cisRA treatment
Fold change Gene title Symbol RARE
2.62 Microseminoprotein, b- MSMB RAR
2.03 collagen, type I, a-1 COL1A1
6.31 Hydroxyacid oxidase 2 (long chain) HAO2
6.19 Hydroxy-d-5-steroid dehydrogenase, 3-b HSD3B1 RAR
5.09 Phospholipase A2, group VII (PAF acetylhydrolase) PLA2G7
4.9 Fatty acid desaturase 1 FADS1 RAR, RXR
4.71 Galanin GAL RAR
4.57 PDZ domain containing 1 PDZK1 RAR, RXR
4.14 Histone 1, H1c HIST1H1C
4.02 Fatty acid binding protein 7, brain FABP7
3.99 Arachidonate 15-lipoxygenase, second type ALOX15B RAR
3.73 Mucin 1, transmembrane MUC1 RXR
3.73 Insulin induced gene 1 INSIG1
3.68 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 HMGCS1 RAR
3.6 Lipidosin BG1 RAR
3.59 Sterol O-acyltransferase SOAT1
3.37 Fatty acid desaturase 2 FADS2 RAR, RXR
Pathways significantly enriched after 8 weeks of 13-cisRA treatment
Pathway term No. of genes in cluster/total no.
of genes with term on gene array
% of genes with RARE or RXRE
Electron transport chain 24 out of 135 76
Fatty acid degradation 12 out of 43 87.5
Mitochondrial fatty acid b-oxidation 11 out of 31 75
Krebs-TCA cycle 10 out of 54 75
Reductive carboxylate cycle (CO2 fixation) 5 out of 14 75
Fatty acid synthesis 8 out of 28 75
Pentose phosphate//GenMAPP 5 out of 13 75
Cholesterol biosynthesis 21 out of 30 75
Biosynthesis of steroids 15 out of 30 70
Terpenoid biosynthesis 6 out of 11 66.7
Microarray data has been deposited in NCBI’s Gene Expression Omnibus (http:www.ncbi.nlm.nih.gov/geo) and is accessible through GEO Series accession
number GSE11792.
See Table S1 for complete list of genes.
All pathway terms have a P-valueo0.0008, which is defined as the probability of seeing x genes with a certain category occurring in a group of k genes at
random, given n annotated genes on the array, of which m genes carry that specific annotation.
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supporting 13-cisRA’s role in sebum
suppression (Table 1).
At 1 week, five gene ontology terms,
three protein domains (lipocalin re-
lated, calcium binding, and latexin),
and one chromosomal location (1q21)
were enriched. The 1q21 locus is the
site of the epidermal differentiation
complex. Five genes on this locus are
affected by isotretinoin: cellular reti-
noic acid binding protein 2 (CRABP2),
S100A2, S100A7, S100A9, and involu-
crin (IVL). Increased CRABP2 expression
supports a previous study demonstrating
increased CRABP2 levels in the patients’
sebaceous glands following 3–16 weeks
of isotretinoin therapy (Sitzmann et al.,
1995). The specific S100 proteins whose
genes are upregulated are induced by
oxidative or inflammatory stress. S100A7
(psoriasin) has antimicrobial effects
against Proprionibacterium acnes and
chemoattractant activity (Eckert et al.,
2004; Lee et al., 2008). Initial upregula-
tion of S100 proteins by 13-cisRA could
relate to the ‘‘acne-flare’’ observed in
some patients receiving retinoids. The
clustering of retinoic acid responsive
genes on 1q21 raises the question of
whether each gene is individually
regulated or whether retinoic acid
affects epigenetic regulation of the
epidermal differentiation complex
through a locus control region, similar
to the b-globin gene locus (Mahajan
et al., 2007).
The promoter regions of all genes
whose expression changed significantly
at 1 week or 8 weeks were analyzed for
retinoid receptor consensus sequences
using Transcriptional Element Search
System and TRANSFAC databases
(Wingender et al., 1996; Schug and
Overton, 1997). Approximately half of
the genes in both data sets contain
retinoic acid receptor response ele-
ments within their promoters, suggest-
ing possible direct gene regulation
through classical nuclear retinoid re-
ceptors. Although 13-cisRA itself does
not activate RAR or RXR, it is isomer-
ized to all-trans retinoic acid, which
can directly activate these receptors
(Allenby et al., 1993; Tsukada et al.,
2000). However, not all gene promoters
contained retinoid receptor consensus
sequences, indicating that indirect
regulation is possible.
This study demonstrates that 13-
cisRA markedly decreases sebaceous
gland size by 8 weeks with a trend
noted at 1 week. These data support the
observation that sebum secretion is
markedly reduced by 13-cisRA as early
as 2 weeks (Stewart et al., 1983;
Hughes and Cunliffe, 1994). The
temporal changes in gene expression
within patient skin induced by isotreti-
noin substantiate many clinical,
histological and biochemical effects
of isotretinoin noted in previous
studies. These data combined with
recent findings regarding isotretinoin’s
effects on apoptosis, cell cycle
arrest, and induction of lipocalin 2
expression suggest that after the initial
induction of apoptosis and cell cycle
arrest within the sebaceous gland; the
skin adopts a wound healing-like pat-
tern of gene expression and subse-
quently undergoes substantial repair
and remodeling as evidenced by in-
creased expression of extracellular ma-
trix proteins (Nelson et al., 2006, 2008).
The mechanism by which isotretinoin
induces long-term or permanent remis-
sion of acne however remains to be
determined.
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TO THE EDITOR
Null mutations in the epidermal barrier
protein filaggrin (FLG) cause ichthyosis
vulgaris (IV, Smith et al., 2006) and are
a major risk factor for eczema and other
atopic diseases (Palmer et al., 2006;
Baurecht et al., 2007; Brown et al.,
2008a; Henderson et al., 2008). About
10% of European patients are
heterozygous for such null mutations
(Sandilands et al., 2006), but clinical
details of their skin phenotype are
sparse. A recent study of 811 English
children reported that mild ichthyosis,
palmar hyperlinearity, and keratosis
pilaris were commoner in carriers of
null mutations (Brown et al., 2008a).
We report the effect of heterozygosity
for FLG null alleles, and age, on the
prevalence of simple subjective or
objective clinical features of ‘‘dry skin’’
in adults and elderly patients not
selected for inflammatory skin disease.
Patients referred for diagnosis of a
discrete skin lesion to dermatology
clinics in Glasgow were recruited in
two age cohorts: young adults 18–40
years (192 patients; 82 men, 110
women), and the elderly 60–75 years
(99 patients; 55 men, 44 women).
Patients were asked not to apply body
moisturizers for 48 hours before their
appointment; sunbed users or those
who had been on a sunny holiday
within 6 weeks were excluded. The
protocol was approved by the South
Glasgow Research Ethics Committee,
conformed to the Declaration of Hel-
sinki Principles, and written informed
consent was obtained. The study took
place in all months of the year, in a
climate without extreme variation in
humidity, and all assessments took
place before genotyping. A question-
naire asked patients whether they
considered they had dry skin (possible
responses, coded 0–3, were not at all, a
little, moderately, or a lot), sensitive
skin (same responses) and how often
they used a moisturizer for the body
(never, now and again, more than once
a week, or daily), and sought a history
of childhood eczema or other diseases.
Trained observers made objective as-
sessments of visible fine scale and of
roughness in each of three body sites
(volar forearms, lower legs, and lower
back), of keratosis pilaris (upper arms
only), and of increased palmar mark-
ings and texture. A simple scoring scale
for each parameter was used: absent
(0), just perceptible (1), obvious (2), and
marked (3). The total score of these
parameters (maximum 27) was used as
a summary measure of ‘‘dry skin’’.
DNA, extracted from whole blood
using standard procedures, was geno-
typed for four FLG null mutations
common in the UK (R501X, 2282del4,
R2447X, and S3247X) as described
(Palmer et al., 2006; Sandilands et al.,
2007) with minor refinements (Table
S1). Statistical comparisons were
made in 284 patients in whom all
four mutations were successfully
typed, between those wild-type se-
quence at all loci (wt) and patients
heterozygous for only one of the muta-
tions (null).
Of 284, 252 (89%) patients were
wild type for all four mutations; 29
(10.2%) were heterozygous for one null
mutation, and 3 (1%) were compound
heterozygotes, R501X/R2447X, 2282del4/
S3247X, and R2447X/S3247X. The fre-
quency of these alleles was consistent
with the previous UK data (Table S2;
Sandilands et al., 2007; Brown et al.,
2008b). Four patients in whom the
assessors commented on marked
scaling consistent with IV included all
three compound heterozygotes; the
fourth was heterozygous only for
R501X but on biopsy showed a reduced
granular layer, consistent with previous
immunohistochemical analysis indica-
tive of an undetected second null
mutation (Sandilands et al., 2007); for
financial reasons, this patient was not
subjected to full sequencing.
Questionnaire results are shown in
Figure 1a and Table S3. Women were
highly significantly more likely than
men to consider they had dry skin (39
vs 11%) or use body moisturizers
regularly (43 vs 7%). Heterozygous
carriers of null mutations were more
likely to think they had dry skinAbbreviation: FLG, filaggrin; IV, ichthyosis vulgaris
1042 Journal of Investigative Dermatology (2009), Volume 129
A Sergeant et al.
Filaggrin Null Alleles and Dry Skin
